Point72 Asia (Singapore)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Point72 Asia (Singapore)’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$36K	Sell	23,874 -35,579	-60%	-$53.3K	0.01%	622
2025 Q2	$69K	Buy	59,453 +41,348	+228%	+$54.5K	0.01%	537
2025 Q1	$28.8K	Buy	18,105 +990	+6%	+$2.13K	0.01%	648
2024 Q4	$51.9K	Buy	+17,115	New	+$56.1K	0.01%	503
2024 Q2	–	Sell	-3,392	Closed	-$53.5K	–	1563
2024 Q1	$53.5K	Buy	+3,392	New	+$46.7K	0.01%	783

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asia (Singapore)'s ZNTL Position: Q3 2025 in Review

Point72 Asia (Singapore) reduced its Zentalis Pharmaceuticals (ZNTL) stake by 60% in Q3 2025, selling an estimated $53.3K and leaving 23,874 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #622.

Point72 Asia (Singapore) first reported a position in ZNTL in Q1 2024 and has held it in 5 quarters since. The position peaked at $69K in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Point72 Asia (Singapore) held 23,874 shares of Zentalis Pharmaceuticals worth $36K as of Q3 2025.
Point72 Asia (Singapore) sold 35,579 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $53.3K.
Zentalis Pharmaceuticals made up 0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #622 holding.
Point72 Asia (Singapore) first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 5 quarters since.
Point72 Asia (Singapore)'s Zentalis Pharmaceuticals position peaked at $69K in Q2 2025.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.